NEW YORK (AP) – Pfizer is spending more than $2 billion in cash to buy a drugmaker focused on cancer treatments. Pfizer will pay $18.50 for each share of Trillium Therapeutics Inc., or more than double the stock’s 60-day weighted average price. Trillium has no products on the market. Its potential treatments include biologics that […]